Among people diagnosed with cutaneous melanoma in the United States, those who live in rural areas have significantly lower rates of survival than those who live in urban areas, results from an analysis of data from the National Cancer Institute showed.
2024
The Froedtert & MCW Cancer Network announces novel cell therapy treatment for advanced melanoma
Milwaukee — Today, the Froedtert & MCW Cancer Network announced it will begin to offer new treatment to patients with advanced melanoma. Lifileucel, created by Iovance, is the first cell therapy treatment to be FDA approved for the deadliest form of skin cancer.
Dual immunotherapy treatment before surgery in melanoma patients
Neoadjuvant immunotherapy given for stage III melanoma, followed by adjuvant therapy only if there is not a deep response to treatment, promises better outcomes for patients than the current standard of care, which is adjuvant immunotherapy alone.
Triplet Immunotherapy Shows Promise in Early-Phase Trial of Untreated Advanced Melanoma
The triplet combination of nivolumab, relatlimab, and ipilimumab offered promising response rates and survival outcomes in patients with untreated advanced melanoma, according to preliminary data from the nonrandomized phase 1/2 RELATIVITY-048 trial (Abstract 9504). Although the results require confirmation in larger randomized trials, the 4-year overall survival (OS) rate seen with the triplet regimen compares favorably with other nivolumab-based combinations in this setting.